2471 - 2480 of 8404 Results
Title
Year
-
RESTRICTEDTitle: Etiology, pathological characteristics, and clinical management of black pleural effusionJournal Name: MedicinePublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 101Issue #: 8Start Page: e28130End Page: e28130Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1097/md.0000000000028130Best OA location URL: https://doi.org/10.1097/md.0000000000028130Citation Count: 6
-
OPENTitle: Nanobodies as allosteric modulators of Parkinson’s disease–associated LRRK2Journal Name: Proceedings of the National Academy of SciencesPublisher: Proceedings of the National Academy of SciencesVol: 119Issue #: 9Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1073/pnas.2112712119Best OA location URL: https://doi.org/10.1073/pnas.2112712119Citation Count: 44
-
RESTRICTEDTitle: Slowing Parkinson’s Disease Progression with Vaccination and Other ImmunotherapiesJournal Name: CNS DrugsPublisher: Springer Science and Business Media LLCVol: 36Issue #: 4Start Page: 327End Page: 343Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s40263-022-00903-7Citation Count: 8
-
OPENTitle: Cerebrovascular Reactivity Across the Entire Brain in Cerebral Amyloid AngiopathyJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 98Issue #: 17Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1212/wnl.0000000000200136Best OA location URL: https://n.neurology.org/content/neurology/98/17/e1716.full.pdfCitation Count: 28
- Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypes2022OPENTitle: Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypesJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 167Issue #:Start Page: 105668End Page: 105668Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.nbd.2022.105668Best OA location URL: https://doi.org/10.1016/j.nbd.2022.105668Citation Count: 22
-
OPENTitle: Defining Utility Values for Chorea Health States in Patients with Huntington’s DiseaseJournal Name: Advances in TherapyPublisher: Springer Science and Business Media LLCVol: 39Issue #: 4Start Page: 1784End Page: 1793Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s12325-022-02046-zBest OA location URL: https://link.springer.com/content/pdf/10.1007/s12325-022-02046-z.pdfCitation Count: 4
- Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads2022OPENTitle: Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beadsJournal Name: eLifePublisher: eLife Sciences Publications, LtdVol: 11Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.7554/elife.73971Best OA location URL: https://doi.org/10.7554/elife.73971Citation Count: 56
- Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study2022OPENTitle: Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension StudyJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.773999Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.773999/pdfCitation Count: 10
- Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease2022OPENTitle: Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s diseaseJournal Name: Molecular NeurodegenerationPublisher: Springer Science and Business Media LLCVol: 17Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1186/s13024-022-00520-4Best OA location URL: https://molecularneurodegeneration.biomedcentral.com/track/pdf/10.1186/s13024-022-00520-4Citation Count: 16
-
RESTRICTEDTitle: Correction to Novel Thienopyrimidine-Based PET Tracers for P2Y12 Receptor Imaging in the BrainJournal Name: ACS Chemical NeurosciencePublisher: American Chemical Society (ACS)Vol: 13Issue #: 6Start Page: 847End Page: 847Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1021/acschemneuro.2c00110Best OA location URL: https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.2c00110Citation Count: 0